Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Risk Assessment in Patients With Polycythemia Vera (PV)

August 11th 2023

Joe Scandura, MD, PhD, reviews how he approaches risk assessment in patients with polycythemia vera and how risk score helps to determine treatment.

Dr Halpern on the MANIFEST Trial of Pelabresib and Ruxolitinib in Myelofibrosis

August 10th 2023

Anna B. Halpern, MD, discusses key efficacy data from the phase 1/2 MANIFEST trial (NCT02158858) investigating the BET inhibitor pelabresib plus ruxolitinib, and highlights the agents clinical significance in patients with myelofibrosis.

Key Trials in the Treatment of Higher-Risk MDS

August 10th 2023

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

August 10th 2023

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Exploring the Future of MF Treatment

August 7th 2023

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Symptom Monitoring in Patients with MF

August 7th 2023

The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.

BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis

August 4th 2023

Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.

Dr Kremyanskaya on the Rationale for Investigating Rusfertide in Phlebotomy-Dependent PV

August 3rd 2023

Marina Kremyanskaya, MD, PhD, discusses the rationale for investigating rusfertide in the phase 2 REVIVE trial for patients with phlebotomy-dependent polycythemia vera.

Oral HMAs in Lower-Risk MDS Treatment

August 3rd 2023

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

August 3rd 2023

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Rusfertide Improves Efficacy Vs Placebo in Phlebotomy-Dependent Polycythemia Vera

July 31st 2023

Marina Kremyanskaya, MD, PhD, details the outcomes of the phase 2 trial, expands on the potential implications for rusfertide in the treatment of patients with PV, and detailed the next steps for investigating the agent in this patient population.

Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF

July 31st 2023

Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.

Sequencing Therapies in Patients with MF

July 31st 2023

Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.

Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in Myelofibrosis

July 28th 2023

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

July 28th 2023

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

July 28th 2023

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

July 25th 2023

The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.

Pacritinib and Fedratinib for the Treatment of MF

July 24th 2023

Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.

COMFORT-I and COMFORT-II Data Review

July 24th 2023

Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.

Dr Halpern on Momelotinib in Myelofibrosis With Anemia

July 20th 2023

Anna B. Halpern, MD, discusses symptom control, transfusion independence, and spleen volume findings with the JAK and ACVR1 inhibitor momelotinib vs the JAK inhibitor ruxolitinib and danazol in patients with myelofibrosis with anemia.